Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 3, 2015, Pages G179-G187

  Pekow, Joel ^a   Meckel, Katherine ^a   Dougherty, Urszula ^a   Butun, Fatma ^a   Mustafi, Reba ^a   Lim, John ^a   Crofton, Charis ^a   Chen, Xindi ^a   Joseph, Loren ^a   Bissonnette, Marc ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Colon; Colon cancer; Distal colon; miR 143; miR 145; Proximal colon; Regional variation

Indexed keywords

APOPTOSIS INHIBITOR 5; DNA; INSULIN RECEPTOR SUBSTRATE 1; K RAS PROTEIN; MICRORNA 143; MICRORNA 145; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEIN; UNCLASSIFIED DRUG; API5 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MICRORNA; MIRN143 MICRORNA, HUMAN; MIRN145 MICRORNA, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; ASCENDING COLON; CELL CYCLE; CELL SURVIVAL; CLINICAL ARTICLE; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DESCENDING COLON; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; COLON; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; YOUNG ADULT;

ADULT; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 7; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84964695251     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00208.2014     Document Type: Article

References (59)

1. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16: 845–850, 2006.
2. Akkiprik M, Ataizi-Celikel C, Dusunceli F, Sonmez O, Gulluoglu BM, Sav A, Ozer A. Clinical significance of p53, K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis 16: 11–17, 2007.
3. Ambros V. The functions of animal microRNAs. Nature 431: 350–355, 2004.
4. Anti M, Armuzzi A, Morini S, Iascone E, Pignataro G, Coco C, Lorenzetti R, Paolucci M, Covino M, Gasbarrini A, Vecchio F, Gasbarrini G. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 48: 238–246, 2001.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, function. Cell 116: 281–297, 2004.
6. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, Collan Y, Pyrhonen S. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28: 3865–3870, 2008.
7. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, Colon/Rectum Carcinomas Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53: 57–64, 2010.
8. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23: 1377–1391, 2004.
9. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 54: 374–384, 2005.
10. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker JT. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes’ C colon cancer. Am J Gastroenterol 95: 2953–2957, 2000.
11. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, Nikiteas N, Pazaiti A, Kittas C, Bastounis E, Gorgoulis VG. E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 24: 3041–3047, 2004.
12. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385–1392, 2009.
13. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE. The colorectal microRNAome. Proc Natl Acad Sci USA 103: 3687–3692, 2006.
14. Dou L, Zheng D, Li J, Li Y, Gao L, Wang L, Yu L. Methylationmediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. Oncogene 31: 507–517, 2012.
15. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92–105, 2009.
16. Gervaz P, Cerottini JP, Bouzourene H, Hahnloser D, Doan CL, Benhattar J, Chaubert P, Secic M, Gillet M, Carethers JM. Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. Surgery 131: 190–197, 2002.
17. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12: 755–762, 2003.
18. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLos One 5: e8836, 2010.
19. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLos One 4: e5717, 2009.
20. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998.
21. Kaz AM, Wong CJ, Dzieciatkowski S, Luo Y, Schoen RE, Grady WM. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics 9: 492–502, 2014.
22. Koestler DC, Li J, Baron JA, Tsongalis GJ, Butterly LF, Goodrich M, Lesseur C, Karagas MR, Marsit CJ, Moore JH, Andrew AS, Srivastava A. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol 27: 145–155, 2014.
23. Krejci P, Pejchalova K, Rosenbloom BE, Rosenfelt FP, Tran EL, Laurell H, Wilcox WR. The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leukoc Biol 82: 1363–1364, 2007.
24. Kubben FJ, Peeters-Haesevoets A, Engels LG, Baeten CG, Schutte B, Arends JW, Stockbrugger RW, Blijham GH. Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation. Gut 35: 530–535, 1994.
25. Liu LU, Holt PR, Krivosheyev V, Moss SF. Human right and left colon differ in epithelial cell apoptosis and in expression of Bak, a pro-apoptotic Bcl-2 homologue. Gut 45: 45–50, 1999.
26. Liu W, Mao SY, Zhu WY. Impact of tiny miRNAs on cancers. World J Gastroenterol 13: 497–502, 2007.
27. ΔΔCT method. Methods 25: 402–408, 2001.
28. Ma QY, Williamson KE, Rowlands BJ. Variability of cell proliferation in the proximal and distal colon of normal rats and rats with dimethylhydrazine induced carcinogenesis. World J Gastroenterol 8: 847–852, 2002.
29. Marx A, Simon P, Simon R, Mirlacher M, Izbicki JR, Yekebas E, Kaifi JT, Terracciano L, Sauter G. AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch 453: 243–248, 2008.
30. McKenna LB, Schug J, Vourekas A, McKenna JB, Bramswig NC, Friedman JR, Kaestner KH. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 139: 1654–1664, 2010.
31. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 15: 2388–2394, 2008.
32. Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882–891, 2003.
33. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 37: 707–718, 2010.
34. Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW, Dyson NJ. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLos Genet 2: e196, 2006.
35. Mulloy R, Salinas S, Philips A, Hipskind RA. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22: 5387–5398, 2003.
36. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 96: 1409–1418, 2007.
37. Nilbert M, Planck M, Fernebro E, Borg A, Johnson A. Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer. Eur J Cancer 35: 942–945, 1999.
38. Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, Toy K, Modrusan Z, Pal N, Zhong F, Chalasani S, Clark H, Arnott ID, Penman ID, Satsangi J, Diehl L. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 57: 1398–1405, 2008.
39. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner SD, Nikiteas N. The impact of tumor location on the histopathologic expression of colorectal cancer. J BUON 11: 317–321, 2006.
40. Patchett SE, Alstead EM, Saunders BP, Hodgson SV, Farthing MJ. Regional proliferative patterns in the colon of patients at risk for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 40: 168–171, 1997.
41. Pekow JR, Dougherty U, Mustafi R, Zhu H, Kocherginsky M, Rubin DT, Hanauer SB, Hart J, Chang EB, Fichera A, Joseph LJ, Bissonnette M. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 18: 94–100, 2012.
42. min/+ tumors, and regulates Sox9. Endocrinology 149: 261–267, 2008.
43. Rohde C, Zhang Y, Reinhardt R, Jeltsch A. BISMA—fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. BMC Bioinformatics 11: 230, 2010.
44. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF, Andersen CL. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416–6424, 2008.
45. Schmitz KJ, Hey S, Schinwald A, Wohlschlaeger J, Baba HA, Worm K, Schmid KW. Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch 455: 49–54, 2009.
46. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810–816, 1999.
47. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582–32590, 2007.
48. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B, Wolff RK. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 50: 196–206, 2011.
49. Snaebjornsson P, Jonasson L, Jonsson T, Moller PH, Theodors A, Jonasson JG. Colon cancer in Iceland—a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer 127: 2645–2653, 2010.
50. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16: 49–58, 2010.
51. Su DM, Zhang Q, Wang X, He P, Zhu YJ, Zhao J, Rennert OM, Su YA. Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther 8: 1292–1304, 2009.
52. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y, Dahiya R. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32: 772–778, 2011.
53. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257–2261, 2006.
54. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 26: 27–34, 2009.
55. Will OC, Leedham SJ, Elia G, Phillips RK, Clark SK, Tomlinson IP. Location in the large bowel influences the APC mutations observed in FAP adenomas. Fam Cancer 9: 389–393, 2010.
56. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, Brant SR, Chakravarti S, Kwon JH. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology 135: 1624–1635, 2008.
57. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647–658, 2009.
58. Yang Y, Chaerkady R, Kandasamy K, Huang TC, Selvan LD, Dwivedi SB, Kent OA, Mendell JT, Pandey A. Identifying targets of miR-143 using a SILAC-based proteomic approach. Mol Biosyst 6: 1873–1882, 2010.
59. 1 regulators. Mol Cancer Res 9: 960–975, 2011.